Herpes labialis - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Herpes labialis - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Herpes labialis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Herpes labialis: Overview
Herpes labialis, also known as HSV-1, or oral herpes, is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus. Symptoms of herpes include painful blisters or ulcers at the site of infection. The prevalence of oral herpes infection is 67% of adults worldwide. Herpes labialis or oral herpes is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus. Cold sores (herpes labialis) usually go away within 1-2 weeks, but they can be treated with antiviral medications, like acyclovir or topical antiviral creams such as docosanol (Abreva), to reduce pain and shorten healing time.
'Herpes labialis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes labialis pipeline landscape is provided which includes the disease overview and Herpes labialis treatment guidelines. The assessment part of the report embraces, in depth Herpes labialis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes labialis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Herpes labialis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Herpes labialis Emerging Drugs
Further product details are provided in the report……..
Herpes labialis: Therapeutic Assessment
This segment of the report provides insights about the different Herpes labialis drugs segregated based on following parameters that define the scope of the report, such as:
Herpes labialis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Herpes labialis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes labialis drugs.
Herpes labialis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Herpes labialis - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Herpes labialis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Herpes labialis: Overview
Herpes labialis, also known as HSV-1, or oral herpes, is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus. Symptoms of herpes include painful blisters or ulcers at the site of infection. The prevalence of oral herpes infection is 67% of adults worldwide. Herpes labialis or oral herpes is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus. Cold sores (herpes labialis) usually go away within 1-2 weeks, but they can be treated with antiviral medications, like acyclovir or topical antiviral creams such as docosanol (Abreva), to reduce pain and shorten healing time.
'Herpes labialis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes labialis pipeline landscape is provided which includes the disease overview and Herpes labialis treatment guidelines. The assessment part of the report embraces, in depth Herpes labialis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes labialis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Herpes labialis R&D. The therapies under development are focused on novel approaches to treat/improve Herpes labialis.
This segment of the Herpes labialis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Herpes labialis Emerging Drugs
- HDIT-101: Heidelberg ImmunoTherapeutics
Further product details are provided in the report……..
Herpes labialis: Therapeutic Assessment
This segment of the report provides insights about the different Herpes labialis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Herpes labialis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Herpes labialis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Herpes labialis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes labialis drugs.
Herpes labialis Report Insights
- Herpes labialis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Herpes labialis drugs?
- How many Herpes labialis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Herpes labialis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Herpes labialis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Herpes labialis and their status?
- What are the key designations that have been granted to the emerging drugs?
- AiCuris
- Heidelberg ImmunoTherapeutics
- Ecogene 21
- Beech Tree Labs
- NanoViricides
- Maxwell Biosciences
- BOR15001L7
- HDIT-101
- Pritelivir
- BTL-TML
- Research programme: Herpes simplex virus nanoparticle therapies
- MXB-009
Introduction
Executive Summary
Herpes labialis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Herpes labialis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
HDIT-101: Heidelberg ImmunoTherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
MXB-009: Maxwell Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Herpes labialis Key Companies
Herpes labialis Key Products
Herpes labialis- Unmet Needs
Herpes labialis- Market Drivers and Barriers
Herpes labialis- Future Perspectives and Conclusion
Herpes labialis Analyst Views
Appendix
Executive Summary
Herpes labialis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Herpes labialis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
HDIT-101: Heidelberg ImmunoTherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
MXB-009: Maxwell Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Herpes labialis Key Companies
Herpes labialis Key Products
Herpes labialis- Unmet Needs
Herpes labialis- Market Drivers and Barriers
Herpes labialis- Future Perspectives and Conclusion
Herpes labialis Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Herpes labialis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Herpes labialis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Herpes labialis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Herpes labialis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
